Physicians' negative experience with Exubera, Pfizer/Nektar's inhaled insulin, may slow adoption of new therapies.
Physicians' negative experience with Exubera, Pfizer/Nektar's inhaled insulin, which has been discontinued, may slow the adoption of new therapies that allow needle-free administration of insulin for Type 1 diabetes. Among needle-free therapies now in development, oral and transdermal insulins hold the greatest promise, but their use will be constrained by dosing variability issues that may discourage physicians from prescribing them. These are some conclusions of a new report on Type 1 diabetes by the market research firm Decision Resources. The report also noted a trend from regular human insulins and neutral protamine Hagedorn (NPH) insulin towards more expensive rapid-acting insulin analogues and long-acting insulin analogues.